Vigmed publishes prospectus concerning the rights issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INOR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONSThe prospectus concerning Vigmed Holding AB’s (publ) (“Vigmed” or the “Company”) rights issue has been approved and registered by the Swedish Financial Supervisory Authority and is available on the Company’s website www.vigmed.com and on Remium’s website www.remium.com. Vigmed has engaged ABG Sundal Collier as financial advisors and Mannheimer Swartling Advokatbyrå as legal advisor in